Analysts Set Harrow, Inc. (NASDAQ:HROW) PT at $69.43

Harrow, Inc. (NASDAQ:HROW) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $69.4286.

HROW has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. B. Riley Financial reiterated a “buy” rating and issued a $65.00 price objective (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. Nomura lowered shares of Harrow to a “neutral” rating in a report on Wednesday, March 18th. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $63.00 price objective on shares of Harrow in a report on Tuesday, May 12th.

Insiders Place Their Bets

In other news, CFO Andrew R. Boll acquired 3,500 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the acquisition, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This represents a 0.43% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adrienne L. Graves acquired 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The stock was purchased at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the acquisition, the director directly owned 1,000 shares in the company, valued at $31,070. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Harrow in the 4th quarter worth about $26,000. KBC Group NV bought a new stake in shares of Harrow during the 1st quarter valued at about $31,000. SBI Securities Co. Ltd. grew its position in shares of Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Harrow during the 2nd quarter valued at about $48,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Harrow by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Performance

NASDAQ:HROW opened at $34.11 on Thursday. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -83.19 and a beta of 0.28. The firm’s fifty day simple moving average is $36.02 and its 200 day simple moving average is $41.92. Harrow has a twelve month low of $27.17 and a twelve month high of $54.85.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The business had revenue of $44.20 million for the quarter, compared to analyst estimates of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same quarter in the previous year, the firm posted ($0.38) EPS. As a group, equities research analysts expect that Harrow will post 0.29 earnings per share for the current fiscal year.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.